The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity

Item

http://www.wikidata.org/entity/Q34524690

Q34524690

about

Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.Reversibility of endothelial dysfunction in diabetes: role of polyphenols.The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence.Taking up the cudgels for the traditional reactive oxygen and nitrogen species detection assays and their use in the cardiovascular system.Carbonyl stress phenomena during chronic infection with Opisthorchis felineus.A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.Formation of 2-nitrophenol from salicylaldehyde as a suitable test for low peroxynitrite fluxes.Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation.Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo.Uncoupling of Vascular Nitric Oxide Synthase Caused by Intermittent Hypoxia.Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.The adverse effects of environmental noise exposure on oxidative stress and cardiovascular risk.Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.Comparison of Pulmonary and Systemic NO- and PGI2-Dependent Endothelial Function in Diabetic Mice.

P2860

Q28072765-B1A63C0A-FDBF-4B4E-BD24-7467A641B1B5 Q28082343-64285BBB-B819-449E-80AC-6F1DA07AAF37 Q36301818-1D9AE8CD-B5AA-4C62-A62A-86064F141402 Q37325818-943717B6-C2C7-4F94-A5F9-80994FE9D348 Q37586729-C2EFECA4-4D04-41E1-976A-646C12B6169D Q37620904-CB0D531E-E225-4147-90FD-0A555E782AEC Q38537119-F433BD58-53F6-41BA-A18D-C4031ADAD803 Q38698841-F31A4CC3-2406-4414-9BBE-7DD749F258A8 Q38793748-34D4D899-4475-457F-90A4-C33F1CA5C866 Q38855635-D461251A-82FE-48DA-8BF8-146A6049EA0C Q38927264-69218C2A-4EF7-4C01-8862-EBB6A4563D6F Q38990014-AE98D7D2-B69B-4E81-B18B-A629ECA13189 Q39140884-610A9982-D5D3-454D-A612-AD0B034EFC10 Q39425969-A5049181-76B1-4AFF-80DC-60EDBA4C9844 Q40051780-CBC60BA7-118B-403B-8E91-FC666B70565F Q40249782-8D5D3805-0A62-45DF-9FED-3172458A12A7 Q41227936-33408B9A-3F78-481D-B172-587AA558F9A6 Q41579741-24FC89C1-B222-4E3E-A974-FB30EFC7E2FC Q41855979-DE8E677F-161F-4E75-8A6D-78E7FC218FA7 Q41974803-FF1AFE28-B805-4099-8D44-AC2D566C102C Q42643495-A3A34535-4301-4A3D-B5DB-30F3EE0410E6 Q47297477-6C48C89D-3FAA-4523-88F6-9840E9C3F321 Q47643546-4382E234-3590-461A-A510-5DC5DA4338E8 Q49343999-CE2C096E-6AE9-4C2E-85D8-E7FB4826783B Q49423096-ECB710D3-DD4B-42F0-BD79-654B272BA265 Q54119005-A32DEAEE-A7CC-47D4-8313-5E0AD312C1FB Q55384960-C8F8AE4A-EDE0-4CFE-A94E-8032ADE8EA68 Q55405814-EB41FA15-C183-4D15-93C2-88FF2FFB639A

P2860

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity

Item

http://www.wikidata.org/entity/Q34524690

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu